|
1. Do the public health recommendations in the guidelines address a priority problem for disadvantaged populations?
|
Discussions on the burden of disease in disadvantaged populations.
|
|
2. Is there a reason to anticipate different effects of intervention in disadvantaged and privileged populations?
|
Discussions on differences between disadvantaged and privileged populations, in terms of biology of the disease, adherence, and baseline risks.
|
|
3. Are the effects of the intervention valued differently by disadvantaged compared to privileged populations?
|
Values may be assessed in guideline development panels through consultations with disadvantaged populations, involvement of their caregivers, reference to relevant research, or transparent reflection.
|
|
4. Is specific attention given to minimizing barriers to implementation in disadvantaged populations?
|
Discussion of barriers to implementation in disadvantaged populations and identification of strategies to overcome these barriers.
|
|
5. Do plans for assessing the impact of the recommendations include disadvantaged populations?
|
Plans for monitoring disadvantaged groups according to place of residence, race, occupation, gender, religion, education, socioeconomic status, or social network and capital.
|
